But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.

The company defends its cancer strategy, and says it's not a me-too developer.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.